Gt-005 clinical trials
Also written GT005.
- studies test it
- 3
- open now
- 0
- in phase 3
- 0
- first study started
- 2018
How each study uses gt-005 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- GT005
- 3
Studies by the year they started
3 studies that test it; most in 2018 (1)
| Year | Studies |
|---|---|
| 2018 | 1 |
| 2019 | 1 |
| 2020 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 0
Gyroscope Therapeutics Limited (3)
Studies
Open first, then newest update. How each study uses gt-005 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- FOCUS: A Phase I/II First in Human Study to Evaluate the Safety and Efficacy of GT005 Administered in Subjects With Dry AMDTerminatedPhase 1/2Gyroscope Therapeutics LimitedNCT03846193Written as GT005
- HORIZON: A Phase II Study to Evaluate the Safety and Efficacy of Two Doses of GT005TerminatedPhase 2Gyroscope Therapeutics LimitedNCT04566445Written as GT005
- EXPLORE: A Phase II Study to Evaluate the Safety and Efficacy of Two Doses of GT005TerminatedPhase 2Gyroscope Therapeutics LimitedNCT04437368Written as GT005